Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695415 | 0.85 | HCAR3 (0.52) | ALDH1A1KCNMA1HCAR3MAPTTDP1 | |
| SCHEMBL30697332 | 0.85 | HCAR3 (0.52) | ALDH1A1KCNMA1HCAR3MAPTTDP1 | |
| SCHEMBL3841711 | 0.84 | LMNA (0.55) | ALDH1A1KCNMA1HCAR3MAPTTDP1 | |
| SCHEMBL468372 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HCAR3MAPTMAPK1KMT2A | |
| SCHEMBL7482776 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KCNMA1HCAR3MAPTTDP1 | |
| SCHEMBL11463783 | 0.82 | KAT2B (0.62) | ALDH1A1KCNMA1HCAR3MAPTTDP1 | |
| SCHEMBL16423449 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HCAR3MAPTMAPK1KMT2A | |
| SCHEMBL16423450 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HCAR3MAPTMAPK1KMT2A | |
| SCHEMBL5113536 | 0.81 | KMT2A (0.70) | ALDH1A1KCNMA1MAPTMAPK1KMT2A | |
| SCHEMBL5113527 | 0.81 | KMT2A (0.70) | ALDH1A1KCNMA1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| CN-102361863-A | Novel bicyclic antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-22 | — | — | CN | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| US-RE30415-E | ANTIINFLAMMATORY AGENTS, ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-RE30314-E | ANTIINFLAMMATORY, ANTITHROMBOTIC | ELI LILLY AND COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4133884-A | Substituted pyrroloquinoxalinones and diones used in treating inflammation in warm blooded mammals | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4087527-A | ANTIINFLAMMATORY AND ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4075206-A | ANTIINFLAMMATORY, ANTITHROMBOTIC | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | ALDH1A1 4235/4885KCNMA1 1287/4885HCAR3 99/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | ALDH1A1 4353/4885KCNMA1 2134/4885HCAR3 188/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | ALDH1A1 4353/4885KCNMA1 2134/4885HCAR3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.